[go: up one dir, main page]

NI200700152A - Usos novedosos para agonistas de estrogeno beta - Google Patents

Usos novedosos para agonistas de estrogeno beta

Info

Publication number
NI200700152A
NI200700152A NI200700152A NI200700152A NI200700152A NI 200700152 A NI200700152 A NI 200700152A NI 200700152 A NI200700152 A NI 200700152A NI 200700152 A NI200700152 A NI 200700152A NI 200700152 A NI200700152 A NI 200700152A
Authority
NI
Nicaragua
Prior art keywords
agonists
strogen
beta
brand new
new uses
Prior art date
Application number
NI200700152A
Other languages
English (en)
Inventor
Mark Day
Heather A Harris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NI200700152A publication Critical patent/NI200700152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Esta invención provee métodos para tratar enfermedades o trastornos cognitivos y síntomas de los mismos con agonistas selectivos de estrógeno beta.
NI200700152A 2004-12-17 2007-06-14 Usos novedosos para agonistas de estrogeno beta NI200700152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
NI200700152A true NI200700152A (es) 2008-06-17

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700152A NI200700152A (es) 2004-12-17 2007-06-14 Usos novedosos para agonistas de estrogeno beta

Country Status (20)

Country Link
US (1) US20060135574A1 (es)
EP (1) EP1824478A2 (es)
JP (1) JP2008524236A (es)
KR (1) KR20070086329A (es)
CN (1) CN101321524A (es)
AR (1) AR051844A1 (es)
AU (1) AU2005316561A1 (es)
BR (1) BRPI0519111A2 (es)
CA (1) CA2590258A1 (es)
GT (1) GT200500370A (es)
IL (1) IL183604A0 (es)
MX (1) MX2007007347A (es)
NI (1) NI200700152A (es)
NO (1) NO20072658L (es)
PA (1) PA8656601A1 (es)
PE (1) PE20061113A1 (es)
RU (1) RU2007120254A (es)
TW (1) TW200637545A (es)
WO (1) WO2006065968A2 (es)
ZA (1) ZA200705103B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641116A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of er.beta. selective ligands
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
EP3782616B1 (en) 2014-09-02 2023-11-01 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
US20210340155A1 (en) * 2017-03-30 2021-11-04 Marquette University Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
KR20010108509A (ko) * 1999-04-16 2001-12-07 다비드 에 질레스 에스트로겐 수용체-β리간드
US20070004713A1 (en) * 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
DE60116109T2 (de) * 2001-11-07 2006-09-07 Schering Ag In vitro Screening nach Liganden des Östrogenrezeptors
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
EP1542665A1 (en) * 2002-09-19 2005-06-22 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
CA2570518A1 (en) * 2004-07-01 2006-01-19 Wyeth Tetracyclic compounds as estrogen ligands

Also Published As

Publication number Publication date
IL183604A0 (en) 2007-10-31
TW200637545A (en) 2006-11-01
MX2007007347A (es) 2007-07-13
PE20061113A1 (es) 2006-11-06
WO2006065968A2 (en) 2006-06-22
KR20070086329A (ko) 2007-08-27
CN101321524A (zh) 2008-12-10
JP2008524236A (ja) 2008-07-10
NO20072658L (no) 2007-09-12
WO2006065968A3 (en) 2008-04-10
CA2590258A1 (en) 2006-06-22
PA8656601A1 (es) 2006-12-07
WO2006065968A8 (en) 2008-09-12
ZA200705103B (en) 2009-11-25
RU2007120254A (ru) 2009-01-27
GT200500370A (es) 2006-07-13
US20060135574A1 (en) 2006-06-22
EP1824478A2 (en) 2007-08-29
AU2005316561A1 (en) 2006-06-22
BRPI0519111A2 (pt) 2008-12-23
AR051844A1 (es) 2007-02-14

Similar Documents

Publication Publication Date Title
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
NL301145I2 (nl) Tirbanibulin
CR20120102A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
CR6735A (es) Substituted arylpyrazines
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
BRPI0610693A2 (pt) métodos para tratamento de transtornos relacionados à ansiedade
CR10310A (es) Compuestos nuevos
HN2005035605A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
ES2356376T8 (es) Procedimiento cosmetico para las axilas.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
NI200700152A (es) Usos novedosos para agonistas de estrogeno beta
BRPI0615163A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
TW200609559A (en) Contact lenses and methods for their design
CR9126A (es) Usos novedosos para agonistas de estrogeno beta
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
BRPI0614480A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos para tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
UY29237A1 (es) Metodos detratamiento y prevencion
ES1057182Y (es) Disposicion para la constitucion de carteles de señalizacion.
ES1057846Y (es) Soporte para piezas de bisuteria o joyeria.